BMS' arlo-cel has shown activity in a trial that could underpin filings in multiple myeloma settings where the four main drug classes have failed.

Commercial CAR-T vs clinical trials in China: compare approval status, screening, costs and what international patients should verify before travelling.

BREAKTHROUGH: CAR-T cell therapy achieves 100% remission rate in severe lupus patients. German trial shows 15 patients living drug-free after single t… #Autoimmunedisease #CARTtherapy #Clinicaltrial #Immunotherapy #Lupustreatment

CARSgen Therapeutics has claimed approval in China for gastric cancer therapy satri-cel, the first CAR-T to be cleared for a solid tumour.

best CAR-T competitive intelligence platform The global CAR-T therapy landscape is evolving at an unprecedented pace. With hundreds of active clinical programs, expanding indications, increasing inves...

🚨 Medical breakthrough: CAR T-cell therapy (previously used only for cancer) has enabled two highly sensitized kidney patients to rec… #CARTtherapy #Clinicaltrial #Immunology #Kidneytransplant #Sensitizedpatients

🧬 Breakthrough discovery: Single protein NFIL3 identified as major barrier to CAR-T cell therapy success. When disabled, engineered immune cells … #Cancerimmunotherapy #CARTtherapy #Cellexhaustion #NFIL3protein #Preclinicalresearch

Track CAR-T pipelines, clinical trials, competitors, and market trends with an AI-powered CAR-T market intelligence platform built for biopharma strategy teams.

🚨 BREAKTHROUGH: CAR-T cell therapy achieves 85% remission rates in autoimmune diseases by 'resetting' the immune system. Unlike traditional treatments, this… #Autoimmunedisease #CARTtherapy #Clinicaltrials #Immunereset #Immunotherapy

A small clinical trial has demonstrated that CAR-T cell therapy, a treatment previously used for certain cancers, could help control HIV long-term. In the study, researchers reprogrammed participants' immune cells to specifically target HIV. Two participants achieved undetectable levels of the virus, maintaining viral suppression for nearly two years and almost a year, respectively, without the need for ongoing antiretroviral therapy. The trial involved nine participants, some of whom did not respond as well, highlighting the importance of early treatment and proper conditioning for the CAR-T cells. This approach aims to create 'sentinel' immune cells that remain active in the body to prevent HIV replication. Unlike prior HIV functional cures, which relied on stem cell transplants from rare donors and were complex and risky, CAR-T therapy could eventually provide a safer and more scalable alternative. Challenges remain, including the high cost and labor-intensive preparation of CAR-T cells, but researchers are exploring in-body production methods to simplify treatment. While the findings are preliminary, they provide a significant proof-of-concept that teaching the immune system to control HIV without continuous medication is possible, offering hope for a functional cure in the future.

Facing high costs or wait times for blood cancer treatment? Explore CAR-T therapy in China with our expert medical concierge guide for global patients.

SPER advanced therapy analytics enhances CAR-T forecasting and pipeline visibility through the CART Navigator AI platform, delivering real-time clinical tracking, market intelligence, and strategic in...

Explore the challenges in CAR-T therapy development, including cost, safety, and discover how CRISPR gene editing is shaping the future of cancer treatment.